{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T01:40:14Z","timestamp":1771465214899,"version":"3.50.1"},"reference-count":33,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.eururo.2018.07.026","type":"journal-article","created":{"date-parts":[[2018,7,30]],"date-time":"2018-07-30T14:00:35Z","timestamp":1532959235000},"page":"623-630","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":53,"title":["A Randomized, Double-blind, Placebo-controlled Trial of Certolizumab Pegol in Women with Refractory Interstitial Cystitis\/Bladder Pain Syndrome"],"prefix":"10.1016","volume":"74","author":[{"given":"Philip C.","family":"Bosch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2018.07.026_bib0170","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.juro.2009.08.133","article-title":"Psychosocial phenotyping in women with interstitial cystitis\/painful bladder syndrome: a case control study","volume":"183","author":"Nickel","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2018.07.026_bib0175","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s00192-010-1252-8","article-title":"Treatment choices, duration, and cost in patients with interstitial cystitis and painful bladder syndrome","volume":"22","author":"Anger","year":"2011","journal-title":"Int Urogynecol J"},{"key":"10.1016\/j.eururo.2018.07.026_bib0180","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1743-6109.2011.02542.x","article-title":"Alkalinized lidocaine and heparin provide immediate relief of pain and urgency in patients with interstitial cystitis","volume":"9","author":"Parsons","year":"2012","journal-title":"J Sex Med"},{"key":"10.1016\/j.eururo.2018.07.026_bib0185","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/ncpuro0874","article-title":"Interstitial cystitis and systemic autoimmune diseases","volume":"4","author":"Van de Merwe","year":"2007","journal-title":"Nat Clin Pract Urol"},{"key":"10.1016\/j.eururo.2018.07.026_bib0190","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/S0090-4295(99)80332-X","article-title":"Interstitial cystitis: unexplained associations with other chronic disease and pain syndromes","volume":"49","author":"Alagiri","year":"1997","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2018.07.026_bib0195","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1111\/j.1479-828X.1999.tb03135.x","article-title":"Oral methotrexate in the management of refractory interstitial cystitis","volume":"39","author":"Moran","year":"1999","journal-title":"Aust N Z Obstet Gynaecol"},{"key":"10.1016\/j.eururo.2018.07.026_bib0200","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1097\/01.ju.0000153612.14639.19","article-title":"Efficacy of prednisone for severe refractory ulcerative interstitial cystitis","volume":"173","author":"Soucy","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2018.07.026_bib0205","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0022-5347(17)71740-5","article-title":"Similarity of interstitial cystitis to lupus erythematosus","volume":"40","author":"Fister","year":"1938","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2018.07.026_bib0210","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.pharmthera.2007.10.001","article-title":"Tumor necrosis factor antagonist mechanisms of action: a comprehensive review","volume":"117","author":"Tracey","year":"2008","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.eururo.2018.07.026_bib0215","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0022-5347(05)64750-7","article-title":"Mast cell activation triggers a urothelial inflammatory response mediated by tumor necrosis factor-\u03b1","volume":"168","author":"Batler","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2018.07.026_bib0220","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/S0022-5347(08)60186-X","article-title":"Interruption of mast cell function effectively inhibits bladder inflammation in an autoimmune cystitis model","volume":"179","author":"Liu","year":"2008","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2018.07.026_bib0225","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0022-5347(17)32739-8","article-title":"Inflammatory mediator profile in urine and bladder wash fluid of patients with interstitial cystitis","volume":"152","author":"Felsen","year":"1994","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2018.07.026_bib0230","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/j.juro.2009.11.007","article-title":"CXCR3 binding chemokine and TNFSF14 over expression in bladder urothelium of patients with ulcerative interstitial cystitis","volume":"183","author":"Ogawa","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2018.07.026_bib0235","doi-asserted-by":"crossref","first-page":"e76779","DOI":"10.1371\/journal.pone.0076779","article-title":"Increased pro-inflammatory cytokines, C-reactive protein and nerve growth factor expressions in serum of patients with interstitial cystitis\/bladder pain syndrome","volume":"8","author":"Jiang","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.eururo.2018.07.026_bib0240","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.juro.2013.06.038","article-title":"A randomized, double-blind, placebo controlled trial of adalimumab in the treatment of interstitial cystitis\/bladder pain syndrome","volume":"191","author":"Bosch","year":"2014","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2018.07.026_bib0245","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.urology.2014.04.011","article-title":"Examination of the significant placebo effect in the treatment of interstitial cystitis\/bladder pain syndrome","volume":"84","author":"Bosch","year":"2014","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2018.07.026_bib0250","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/S0090-4295(99)80333-1","article-title":"The interstitial cystitis symptom index and problem index","volume":"49","author":"O\u2019Leary","year":"1997","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2018.07.026_bib0255","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1097\/01.ju.0000083020.06212.3d","article-title":"A pilot clinical trial of oral pentosan polysulfate and oral hydroxyzine in patients with interstitial cystitis","volume":"170","author":"Sant","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2018.07.026_bib0260","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/S0090-4295(01)01126-8","article-title":"Psychometric validation of the O\u2019Leary-Sant interstitial cystitis symptom index in a clinical trial of pentosan polysulfate sodium","volume":"57","author":"Lubeck","year":"2001","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2018.07.026_bib0265","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.urology.2005.07.014","article-title":"Responsiveness of symptom scales for interstitial cystitis","volume":"67","author":"Propert","year":"2006","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2018.07.026_bib0270","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0304-3959(01)00349-9","article-title":"Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain scale","volume":"94","author":"Farrar","year":"2001","journal-title":"Pain"},{"key":"10.1016\/j.eururo.2018.07.026_bib0275","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1136\/ard.2008.099291","article-title":"Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study","volume":"68","author":"Fleischmann","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.eururo.2018.07.026_bib0280","doi-asserted-by":"crossref","first-page":"e000119","DOI":"10.1136\/rmdopen-2015-000119","article-title":"Effect of certolizumab pegol over 96 weeks in patients with psoriatic arthritis with and without prior antitumor necrosis factor exposure","volume":"1","author":"Mease","year":"2015","journal-title":"RMD Open"},{"key":"10.1016\/j.eururo.2018.07.026_bib0285","doi-asserted-by":"crossref","first-page":"331","DOI":"10.2165\/00063030-200822050-00005","article-title":"A pegylated Fab\u2019 fragment against tumor necrosis factor for the treatment of Crohn's disease: exploring a new mechanism of action","volume":"22","author":"Bourne","year":"2008","journal-title":"Biodrugs"},{"key":"10.1016\/j.eururo.2018.07.026_bib0290","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1002\/ibd.20225","article-title":"Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor \u03b1 agents","volume":"13","author":"Nesbitt","year":"2007","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.eururo.2018.07.026_bib0295","doi-asserted-by":"crossref","first-page":"A61","DOI":"10.1136\/ard.2010.129650f","article-title":"Differential distribution of a pegylated Fab\u2019 into inflamed versus normal tissue compared with an IGG in arthritis and colitis models","volume":"69","author":"Marenzana","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.eururo.2018.07.026_bib0300","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1056\/NEJMoa062897","article-title":"Maintenance therapy with certolizumab pegol for Crohn's Disease","volume":"357","author":"Schreiber","year":"2007","journal-title":"NEJM"},{"key":"10.1016\/j.eururo.2018.07.026_bib0305","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.juro.2015.10.178","article-title":"Tanezumab reduces pain in women with interstitial cystitis\/bladder pain syndrome and patients with nonurological associated somatic syndromes","volume":"195","author":"Nickel","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2018.07.026_bib0310","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12894-016-0193-z","article-title":"Fulranumab in patients with interstitial cystitis\/bladder pain syndrome: observations from a randomized, double-blind, placebo-controlled study","volume":"17","author":"Wang","year":"2017","journal-title":"BMC Urol"},{"key":"10.1016\/j.eururo.2018.07.026_bib0315","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/0167-5699(93)90244-F","article-title":"Defining criteria for autoimmune diseases (Witebsky's postulates revisited)","volume":"14","author":"Rose","year":"1993","journal-title":"Immunol Today"},{"key":"10.1016\/j.eururo.2018.07.026_bib0320","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.urology.2014.03.001","article-title":"Phenotype-directed management of interstitial cystitis\/bladder pain syndrome","volume":"84","author":"Nickel","year":"2014","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2018.07.026_bib0325","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0022-5347(17)41529-1","article-title":"Summary of the National Institute of Arthritis, Diabetes, Digestive and Kidney Diseases Workshop on Interstitial Cystitis, National Institute of Health, Bethesda, Maryland, August 28\u201329, 1987","volume":"140","author":"Gillenwater","year":"1988","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2018.07.026_bib0330","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.eururo.2007.09.019","article-title":"Diagnostic criteria, classification, and nomenclature for painful bladder syndrome\/interstitial cystitis: an ESSIC proposal","volume":"53","author":"van de Merwe","year":"2008","journal-title":"Eur Urol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283818305487?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283818305487?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,10]],"date-time":"2018-10-10T01:20:34Z","timestamp":1539134434000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283818305487"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["S0302283818305487"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2018.07.026","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Randomized, Double-blind, Placebo-controlled Trial of Certolizumab Pegol in Women with Refractory Interstitial Cystitis\/Bladder Pain Syndrome","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2018.07.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}